SGBCC 2023 Expert Voting: Surgical Treatment

SGBCC 2023 Expert Voting: Surgical Treatment

2023.10.12
The 18th St. Gallen International Breast Cancer Conference (SGBCC 2023) took place in Vienna, the "City of Music," from March 15th to 18th, 2023. SGBCC gathered breast cancer opinion leaders from around the world to discuss and vote on the latest and most controversial topics in early breast cancer diagnosis and treatment, culminating in the biennial St. Gallen International Expert Consensus on Early Breast Cancer. On the final day of the conference, the expert voting session took center stage. Oncology Frontier has  compiled  the following summary of the expert votes on surgical treatment.
2023 SGBCC Expert Voting: Early Treatment Decisions for Triple-Negative Breast Cancer

2023 SGBCC Expert Voting: Early Treatment Decisions for Triple-Negative Breast Cancer

2023.10.12
The 18th St. Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. SGBCC brought together breast cancer opinion leaders from around the world to discuss and vote on the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer. This resulted in the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years.
SGBCC International Dialogue | Dr. JianZhang  Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk?

SGBCC International Dialogue | Dr. JianZhang  Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk?

2023.10.12
The 18th St. Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Breast cancer experts from around the world gathered at this conference to discuss the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer, leading to the formation of the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years. Oncology Frontier invited Dr. Jian Zhang from Fudan University Affiliated Cancer Hospital to have an in-depth discussion with Dr. Nadia Harbeck from the University of Munich on the topic of whether chemotherapy is needed for patients with low genetic risk but high clinical risk (ER+/HER2-) breast cancer.
SGBCC 2023 | Academician  BingheXu: Breast Cancer Treatment and Research – An Asian Perspective

SGBCC 2023 | Academician  BingheXu: Breast Cancer Treatment and Research – An Asian Perspective

2023.10.12
The 18th St.Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Academician Binghe Xu  from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered a presentation titled "Breast Cancer Treatment and Research - An Asian Perspective" during the "Session 10: Global Perspective on Breast Cancer Treatment." After his presentation, Academician Binghe Xu  had an interview with Oncology Frontier to discuss related content.
SGBCC  International Dialogue|Dr. LiZhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

SGBCC  International Dialogue|Dr. LiZhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

2023.10.12
Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "If you achieve pCR after neoadjuvant, do you need adjuvant therapy?" drew global expert attention. Oncology Frontier had  invited Dr. Li Zhu from Shanghai Jiao Tong University School of Medicine, First People's Hospital, and Dr. Giuseppe Curigliano from the University of Milan School of Medicine to engage in an in-depth discussion on this topic.
AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

2023.10.12
According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo combined with chemotherapy. [1,2]
Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

2023.10.12
Thymoma is one of the most common primary tumors in the anterior mediastinum, representing a group of diseases originating from different thymic epithelial cells, characterized by unique clinical and pathological features, often accompanied by various paraneoplastic syndromes. During the "Multidisciplinary Oncology Committee" session held at the 2023 European Lung Cancer Congress (ELCC), several experts discussed the treatment strategies for Stage III thymoma based on a case study. Dr. Andreas Rimner from Memorial Sloan Kettering Cancer Center presented on "The Timing of Radiotherapy in the Treatment of Stage III Thymoma." In an interview with Oncology Frontier, Andreas Rimner shares insights into the role of radiotherapy in the treatment of Stage III thymoma.
Interview with Dr. Martin Reck at ELCC 2023

Interview with Dr. Martin Reck at ELCC 2023

2023.10.12
The 2023 European Lung Cancer Congress (ELCC) recently concluded in Copenhagen. In an interview with Oncology Frontier, 2023 ELCC Scientific Co-Chairs Professor Martin Reck reviewed the most significant oral presentations of the conference and shared insights on the selection of first-line immunotherapy regimens.
Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

2023.10.12
On the first day of the 2023 European Lung Cancer Congress (ELCC), during the oral presentation session, Dr. P. Garrido Lopez from Ramón y Cajal University Hospital in Madrid, Spain, presented the long-term efficacy, safety, and predictive factors of amivantamab in the treatment of platinum-treated EGFR exon 20 insertion (EGFR ex20ins) mutant advanced non-small cell lung cancer (NSCLC) patients in the CHRYSALIS trial (Abstract No. 3O). In an interview with "Tumor Insight," P. Garrido Lopez further elucidated the results of the CHRYSALIS trial and its clinical significance.